ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M

Oric Pharmaceuticals, Inc.

Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.
Entered clinical trial collaboration with Bayer to supply darolutamide at no cost for Himalayas-1; ORIC retains full rights to rinzimetostat.
Cash and investments $387.6M as of June 30, 2026; includes $59.9M net proceeds from ATM; runway into 2H 2028.
R&D expenses $36.3M for Q2 2026, up from $30.5M YoY; G&A $9.0M, up from $8.5M.
Anticipated milestones: rinzimetostat program update 2H 2026; enozertinib data at ESMO October 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.